Addex Therapeutics vs Jupiter Neurosciences
ADXN and JUNS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADXN | JUNS |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.3M |
| Share price | $3.83 | $1.70 |
| Change, 1 year | −55.5% | −98.3% |
| Change, 5 years | −97.3% | – |
| Beta (5Y) | 1.84 | −0.18 |
| Employees | 3 | 5 |
| StockData Score | ||
| Total score | 0 | 0 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −92.6% | – |
| Revenue growth, 5Y average | −61.6% | – |
| EPS growth (TTM) | −186% | – |
| Profitability | ||
| Operating margin | −9391% | – |
| FCF margin | −7244% | – |
| Return on equity | – | −1889% |
| Financial health | ||
| Interest coverage | −181.0× | −36.0× (better) |
| Current ratio | 0.76 (better) | 0.66 |
| Altman Z-score | – | −23.63 |
| Piotroski F-score | – | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | 2.2% |
| Held by insiders | 15.5% | – |
Go deeper
- ADXN stock overview
- ADXN income statement
- ADXN valuation and score
- JUNS stock overview
- JUNS income statement
- JUNS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.